Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Destiny Pharma

Latest From Destiny Pharma

UK Pilots 'Revolutionary And Needed' Antibiotic Payment System

The UK National Health Service is to test the world's first ‘subscription’ payment model to tempt drug makers to develop new products for resistant infections.

United Kingdom Government Payers

Italfarmaco Options Inhaled Teicoplanin For MRSA Lung Infections

Italfarmaco and Neupharma plan to collaborate on the development of a new inhaled formulation of a Gram-positive targeted antibiotic for MRSA infections in cystic fibrosis.


Deals Infectious Diseases

Tech Transfer Roundup: J&J Houses JPOD Incubator At University Of Pennsylvania

Pascal and Oblato separately license therapeutic candidates for glioblastoma multiforme, while Cabaletta emerges from UPenn with novel program for CAAR-T therapies in B-cell mediated autoimmune disease.

Commercial Deals

Destiny Pharma's XF-73 Being Studied For Diabetic Foot Ulcers, Burns Too

One year after its IPO, UK-based Destiny Pharma's CEO tells Scrip it's on track with US development of its lead antimicrobial asset XF-73 for prevention of post-operative infections and will also develop a new formulation to treat infections in diabetic foot ulcers and burn wounds.

Business Strategies Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Destiny Pharma
  • Senior Management
  • Neil Clark, CEO
    Simon Sacerdoti, CFO
    William Love, PhD, CSO
  • Contact Info
  • Destiny Pharma
    Phone: (44) 1273704440
    Sussex Innovation Centre
    Sci. Park Sq.
    Falmer, Brighton, BN1 9SB